Zimmer Biomet Holdings (MEX:ZBH) Piotroski F-Score: 6 (As of Jul. 03, 2026) — Near Median


MEX:ZBH Zimmer Biomet Holdings Inc MEX:ZBH
59 GF Score
Price MXN1,502.00
GF Value MXN2,166.88
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Piotroski F-Score?

Zimmer Biomet Holdings MEX:ZBH 59 Piotroski F-Score is 6 as of Jul. 03, 2026, which is at its 10-year median of 6.00. GuruFocus rates MEX:ZBH with a GF Score™ of 59/100 and a GF Value™ of MXN2,166.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 81.14% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zimmer Biomet Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zimmer Biomet Holdings's Piotroski F-Score or its related term are showing as below:

MEX:ZBH' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Zimmer Biomet Holdings was 8. The lowest was 3. And the median was 6.

Zimmer Biomet Holdings  (MEX:ZBH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zimmer Biomet Holdings Piotroski F-Score Related Terms


Zimmer Biomet Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Piotroski F-Score Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 8.00 6.00 6.00

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 6.00 6.00

MEX:ZBH vs STE, PEN, GMED: Piotroski F-Score Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Piotroski F-Score falls into.


MEX:ZBH
59GF Score
Zimmer Biomet Holdings Inc MEX:ZBH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 2877.102 + 4235.676 + 2508.194 + 4293.586 = MXN13,915 Mil.
Cash Flow from Operations was 7121.203 + 7680.717 + 9316.149 + 6480.952 = MXN30,599 Mil.
Revenue was 39113.897 + 36714.082 + 40399.389 + 37628.835 = MXN153,856 Mil.
Gross Profit was 27963.245 + 26454.171 + 26131.672 + 27238.393 = MXN107,787 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(453842.663 + 430531.541 + 430868.57 + 415782.223 + 409731.797) / 5 = MXN428151.3588 Mil.
Total Assets at the begining of this year (Mar25) was MXN453,843 Mil.
Long-Term Debt & Capital Lease Obligation was MXN113,518 Mil.
Total Current Assets was MXN89,487 Mil.
Total Current Liabilities was MXN51,651 Mil.
Net Income was 4448.121 + 4904.854 + 4994.94 + 3723.392 = MXN18,071 Mil.

Revenue was 35577.64 + 35919.045 + 42195.252 + 39056.75 = MXN152,749 Mil.
Gross Profit was 25435.631 + 25313.85 + 29959.213 + 27808.831 = MXN108,518 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(356029.501 + 394248.617 + 427679.223 + 445588.287 + 453842.663) / 5 = MXN415477.6582 Mil.
Total Assets at the begining of last year (Mar24) was MXN356,030 Mil.
Long-Term Debt & Capital Lease Obligation was MXN134,539 Mil.
Total Current Assets was MXN114,365 Mil.
Total Current Liabilities was MXN46,950 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zimmer Biomet Holdings's current Net Income (TTM) was 13,915. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zimmer Biomet Holdings's current Cash Flow from Operations (TTM) was 30,599. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=13914.558/453842.663
=0.03065943

ROA (Last Year)=Net Income/Total Assets (Mar24)
=18071.307/356029.501
=0.05075789

Zimmer Biomet Holdings's return on assets of this year was 0.03065943. Zimmer Biomet Holdings's return on assets of last year was 0.05075789. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zimmer Biomet Holdings's current Net Income (TTM) was 13,915. Zimmer Biomet Holdings's current Cash Flow from Operations (TTM) was 30,599. ==> 30,599 > 13,915 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=113517.65/428151.3588
=0.26513439

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=134539.261/415477.6582
=0.32381828

Zimmer Biomet Holdings's gearing of this year was 0.26513439. Zimmer Biomet Holdings's gearing of last year was 0.32381828. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=89487.274/51651.063
=1.73253499

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=114365.43/46949.523
=2.43592315

Zimmer Biomet Holdings's current ratio of this year was 1.73253499. Zimmer Biomet Holdings's current ratio of last year was 2.43592315. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zimmer Biomet Holdings's number of shares in issue this year was 195.8. Zimmer Biomet Holdings's number of shares in issue last year was 199.7. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=107787.481/153856.203
=0.70057287

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=108517.525/152748.687
=0.7104318

Zimmer Biomet Holdings's gross margin of this year was 0.70057287. Zimmer Biomet Holdings's gross margin of last year was 0.7104318. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=153856.203/453842.663
=0.3390078

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=152748.687/356029.501
=0.42903379

Zimmer Biomet Holdings's asset turnover of this year was 0.3390078. Zimmer Biomet Holdings's asset turnover of last year was 0.42903379. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zimmer Biomet Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Zimmer Biomet Holdings (MEX:ZBH) has a Piotroski F-Score of 6 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zimmer Biomet Holdings and its competitors. This is near median its historical median of 6.00. Over the past decade, Zimmer Biomet Holdings' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Zimmer Biomet Holdings ranks #152 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Zimmer Biomet Holdings' Piotroski F-Score too high?
Zimmer Biomet Holdings' current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Zimmer Biomet Holdings' value of 6 is 20% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #152 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Piotroski F-Score compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #152 out of 806 companies for Piotroski F-Score. This places Zimmer Biomet Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Zimmer Biomet Holdings' value of 6 is 20% above this benchmark. Historically, Zimmer Biomet Holdings' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (MEX:ZBH) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,166.88, compared to a current price of MXN1,502.00 — trading 30.7% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Zimmer Biomet Holdings' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zimmer Biomet Holdings (MEX:ZBH), the current Piotroski F-Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (MEX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of MXN1,502.00 is trading 30.7% below its estimated GF Value™ of MXN2,166.88. GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.

Key valuation signals for MEX:ZBH:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: MXN2,166.88 vs. price of MXN1,502.00 (30.7% below fair value)
  • GF Score™: 59/100 with 3 warning signs
  • Industry Position: 20% above the Medical Devices & Instruments median (#152 of 806)

No single metric tells the full story. See the MEX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
59GF Score

Get the complete analysis for MEX:ZBH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,502.00
Price
MXN2,166.88
GF Value